Navigation Links
Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement
Date:6/2/2008

Regulatory Hurdle Clears Way for Approval of Merger

CHICAGO, June 2 /PRNewswire-FirstCall/ -- Allscripts, the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, announced today that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, with respect to the merger agreement announced on March 18, 2008 between Allscripts and Misys Healthcare to form Allscripts-Misys Healthcare Solutions, Inc., has expired.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b)

The expiration of the Hart-Scott-Rodino waiting period satisfies one of the closing conditions. The transaction remains subject to other customary closing conditions.

Misys Healthcare is a division of Misys plc (FTSE: MSY.L), the global applications software and services company.

About Allscripts

Allscripts (Nasdaq: MDRX) is the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare. The company's unique solutions inform, connect and transform healthcare, delivering improved care at lower cost. More than 40,000 physicians and thousands of other healthcare professionals in clinics, hospitals and extended care facilities nationwide utilize Allscripts to automate everyday tasks such as writing prescriptions, documenting patient care, managing billing and scheduling, and safely discharging patients, as well as to connect with key information and stakeholders in the healthcare system. To learn more, visit Allscripts at htt
'/>"/>

SOURCE Allscripts
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
2. PCMA Statement on Independent Pharmacy Antitrust Legislation
3. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
4. Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab
5. New Technology at Unitrin Direct Gives Customers an Alternative to Waiting
6. Radiation seed implant decreases risk of death over watchful waiting
7. New Heart Pump Helps Women Awaiting Transplants
8. Governor Rendell Offers Coverage to 29,000 on AdultBasic Waiting List; Unveils New Policy to Improve Quality of Care for the Low-Income and Pennsylvanians With Disabilities
9. Blacks awaiting lung transplants more likely to die or be denied than whites
10. Blacks Awaiting Lung Transplants Face Poorer Outcomes
11. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Precyse Executive Authors New Book, The Legal Health Record 2Health News:In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish 2Health News:Natural Disaster Rescue Teams at Public Health Facilities Across the Country Learn from Katrina Failures 2Health News:Natural Disaster Rescue Teams at Public Health Facilities Across the Country Learn from Katrina Failures 3Health News:AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance 2Health News:AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance 3Health News:UT Southwestern scientist receives NIH Director's New Innovator Award 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 1Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 2Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 3Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 1Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 2Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 3SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 1SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 2SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 3